LumiraDx Limited

Good day, and thank you for standing by. Welcome to the LumiraDx fourth quarter 2021 earnings call. At this time, all participant lines are in listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star, then 1 on your telephone keypad. Please be advised, today's conference may be recorded. If you require operator assistance during the call, please press star, then 0. I'd now like to hand the conference over to your host today, Colleen McMillan, Vice President, Communications. Please go ahead.

Hello, everyone. We'd like to welcome you to today's call to discuss Lumiere DX's fourth quarter and full year 2021 financial results issued earlier this morning. With us are Lumiere DX's Chairman and CEO, Ron Zwanziger, Chief Financial Officer, Dorian LeBlanc, and Chief Product Officer, Pooja Patek. The press release announcing our financial results is posted on the investor relations section at the company's website at LumiraDX.com. Before we begin, I would like to caution listeners that any statements we make today, other than historical facts, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please be aware that all such forward-looking statements involve risk and uncertainty and such as those detailed in our proxy statement and prospectus filed with the SEC on September 3, 2021, and other filings with the SEC. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially. Also, during the course of today's call, we may refer to certain non-IFRS financial measures. There is a reconciliation schedule showing the IFRS versus non-IFRS results, currently available in our press release issued earlier today, which can be found on our website at LumiraDX.com. I will now turn the call over to Ron Zwanziger for opening remarks. We'll then provide financial and business updates before answering questions. Ron?

Thank you, Colleen, and thank you all for joining the call today. Our company delivered a strong quarter and a year of progress, and we're just getting started on our journey of transforming community-based care. We're providing fast, accurate, and comprehensive diagnostic information to healthcare providers to make point of care diagnostics affordable and accessible for every individual in the world. Our next generation platform is proving its value and impact with a wide range of customers. The fourth quarter and full year 21 numbers underscore our tremendous growth potential. More broadly, the pandemic has accelerated our vision and deployment of our next generation platform. and enable the shipment of more than 21,000 platforms through the end of 21 and approximately 4,000 more expected in this quarter. The success is being driven by the positive customer experience and clear competitive advantages of the NumeriDx solutions compared both to legacy point-of-care diagnostics and central lab solutions. We currently have eight tests in the market, and our microfluidic technology and platform have been proven to meet the market needs for fast, high sensitivity, convenient, and connected diagnostic test results for health systems, emergency rooms, retail pharmacy chains, and other community settings. Let me give you a few case studies of the impact of our platform with major customers. At one West Coast U.S. health system customer, the platform installed base grew from seven in the first quarter of 21 to 337 this year, as their confidence increased about the speed, accuracy, and sensitivity of our rapid antigen COVID testing with the Lumira DX microfluidic technology. What's notable is that they expanded the use cases throughout the year, starting with initial focus on physician office labs and then replacing point-of-care molecular systems for urgent care, pharmacy, hospital labs, and surgery. As we deepen the partnership, this customer has come to understand both our platform and our R&D efforts, and has strong interest in the menu of diagnostic tests that can be performed on our platform. A second U.S. health system customer in the Midwest monitored our platform performance versus their lab PCR method for 12 months before implementing it in critical use cases such as pre-surgery testing. With this change, the customer was able to substantially improve turnaround times for pre-surgery patients. I'd also like to highlight how our platform is being used for other conditions besides COVID. In Sweden, our D-dimer tests are changing the standard of care for aiding in the diagnosis of deep vein thrombosis and pulmonary embolism. These conditions are a leading cause of death and may be ruled out with a D-dimer test, but an older rapid testing program had to be discontinued to a high rate of false positives and unnecessary hospitalization admissions. The Lumira DX D-diamond test provides lab-comparable results using a finger-sync sample and is being deployed successfully in GP offices in southern Sweden. We're now exploring opportunities to leverage the portability, digital results, and data connectivity of our solution to enable additional use cases, such as mobile teams, ambulances, and emergency departments, as well as broaden the test menu with troponin and CRP. Finally, In Gloucestershire, England, LumiraDx was brought in as a single integrated point of care solution across the health system, bridging primary and secondary care. The LumiraDx platform implementation has reduced the burden of the healthcare system by triaging patients in community care settings before they arrive at the hospital or ambulatory services. Using one platform to support a number of tests, including COVID antigen, D-dimer, and CRP, has also streamlined resources and reduced costs to the Gloucestershire system. These customer case studies should give you a sense of the growing validation by healthcare providers and resulting market adoption and the use cases for our platforms. This and the opportunities for our fast lab solutions will be critical factors for our growth this year, even as we meet the customer needs for COVID testing and navigate the unpredictability of the coronavirus. At the same time, we remain focused on delivering very significant non-COVID revenues over the next several years. We're pursuing long-term growth in the $50 billion addressable market for our platform by transforming point-of-care diagnostics and making progress in our pipeline of 30-plus diagnostic tests for common health conditions, including infectious diseases, cardiovascular disease, diabetes, and coagulation disorders. I will now hand things over to Dorian to go into our financial performance. Dorian? Thanks, Ron.